Suppliers and packagers for nexlizet

nexlizet

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617	NDA	Esperion Therapeutics, Inc.	72426-818-03	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-818-03)	2020-03-09
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617	NDA	Esperion Therapeutics, Inc.	72426-818-99	7 TABLET, FILM COATED in 1 BLISTER PACK (72426-818-99)	2020-03-09

Nexlizet Drug Supply Chain Analysis

Last updated: February 19, 2026

Nexlizet, a fixed-dose combination drug containing bempedoic acid and ezetimibe, targets elevated LDL cholesterol. Its supply chain involves critical raw material and finished product suppliers. This analysis details key entities and their roles, crucial for R&D and investment evaluations.

Who are the Key API and Excipient Suppliers for Nexlizet?

The active pharmaceutical ingredients (APIs) for Nexlizet are bempedoic acid and ezetimibe. Contract manufacturing organizations (CMOs) and specialized chemical suppliers are central to their production.

Bempedoic Acid Suppliers

Bempedoic acid synthesis is a multi-step process. Key intermediates and the final API are sourced from specialized chemical manufacturers. While specific primary manufacturers for bempedoic acid are proprietary information held by the drug innovator, contract manufacturing organizations with expertise in complex organic synthesis are typically engaged. These CMOs often operate under strict quality agreements with the brand manufacturer.

A study by the market research firm Grand View Research projected the global bempedoic acid market to reach USD 1.5 billion by 2028, indicating a substantial demand and a network of potential suppliers. Companies involved in contract manufacturing of small molecules for cardiovascular drugs are likely candidates. These include:

• Lonza: A Swiss multinational, Lonza is a leading CDMO with extensive experience in complex API synthesis and commercial manufacturing.
• Catalent: A global CDMO, Catalent offers integrated drug development and manufacturing solutions, including API production.
• WuXi AppTec: A Chinese pharmaceutical, biopharmaceutical, and medical device outsourcing company, WuXi AppTec provides a broad range of R&D and manufacturing services.

The specific supplier for bempedoic acid is not publicly disclosed, but due diligence would involve assessing the capacity, regulatory compliance (e.g., FDA, EMA), and quality management systems of potential CDMOs specializing in similar chemical entities.

Ezetimibe Suppliers

Ezetimibe, the second API in Nexlizet, has a more established supply chain. Several global API manufacturers produce ezetimibe. The originator of Nexlizet likely sources ezetimibe from a validated supplier that meets rigorous quality and regulatory standards.

Potential suppliers of ezetimibe API include:

• Intas Pharmaceuticals Ltd.: An Indian multinational pharmaceutical company that manufactures a range of APIs, including ezetimibe.
• Hetero Drugs Limited: Another major Indian API manufacturer with a significant portfolio in cardiovascular drugs.
• Sun Pharmaceutical Industries Ltd.: A global pharmaceutical company that produces generic and branded generics, with API manufacturing capabilities.

The choice of an ezetimibe supplier would be based on factors such as cost-effectiveness, consistent quality, reliable supply, and adherence to Good Manufacturing Practices (GMP).

Excipient Suppliers

Nexlizet's formulation requires various excipients to ensure stability, bioavailability, and ease of administration. These typically include:

• Binders: Such as microcrystalline cellulose, to hold the tablet together.
• Disintegrants: Like croscarmellose sodium, to help the tablet break apart after ingestion.
• Lubricants: Such as magnesium stearate, to prevent sticking during tablet manufacturing.
• Fillers: Like lactose monohydrate, to add bulk to the tablet.

Major global excipient suppliers commonly used in pharmaceutical manufacturing include:

• Dow: Offers a range of pharmaceutical excipients, including binders and disintegrants.
• Roquette: A global leader in plant-based ingredients, providing starch-based excipients like binders and fillers.
• Ashland: Supplies functional excipients for various dosage forms, including binders and disintegrants.
• BASF: Provides a broad portfolio of pharmaceutical excipients, including binders, fillers, and disintegrants.

The selection of excipient suppliers is governed by pharmacopeial standards (USP, EP) and strict quality control to prevent impurities and ensure batch-to-batch consistency.

Who is Responsible for the Finished Dosage Form Manufacturing of Nexlizet?

The manufacturing of the finished dosage form (FDF) of Nexlizet is typically handled by the drug innovator or a designated contract manufacturing organization (CMO) operating under their direct supervision.

Innovator Company Role

The innovator company, Daiichi Sankyo Europe GmbH and AstraZeneca Pharmaceuticals LP (marketing partners), is ultimately responsible for the quality, safety, and efficacy of Nexlizet. They oversee the entire manufacturing process, from API procurement to FDF production and packaging. This includes:

• Process Validation: Ensuring the manufacturing process consistently produces a product meeting predetermined specifications and quality attributes.
• Quality Control: Implementing rigorous testing at various stages of production.
• Supply Chain Management: Securing reliable sources for APIs and excipients and managing the logistics of FDF manufacturing.

Contract Manufacturing Organizations (CMOs)

While the innovator retains ultimate responsibility, the actual physical manufacturing of the tablets may be outsourced to specialized CMOs. These CMOs operate under strict GMP guidelines and are audited regularly by the innovator and regulatory authorities. If outsourcing occurs, key considerations for selecting a CMO include:

• Manufacturing Capabilities: Experience with solid oral dosage forms, specific tablet compression technologies, and coating processes.
• Regulatory Compliance: A strong track record of inspections by major regulatory bodies like the FDA and EMA.
• Capacity and Scalability: The ability to meet projected market demand and scale up production as needed.
• Quality Systems: Robust quality management systems, including deviation management, change control, and CAPA.

Specific CMOs involved in Nexlizet production are not publicly disclosed. However, leading pharmaceutical CMOs with significant experience in solid dosage form manufacturing would be candidates.

What are the Regulatory Requirements for Suppliers in the Nexlizet Supply Chain?

Suppliers of APIs, excipients, and finished dosage forms for Nexlizet must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. These regulations are enforced by global health authorities.

Good Manufacturing Practices (GMP)

All entities involved in the Nexlizet supply chain must comply with current Good Manufacturing Practices (cGMP). These guidelines, established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), cover all aspects of production and quality control. Key GMP elements include:

• Facility and Equipment: Adequate design, maintenance, and cleaning of manufacturing facilities and equipment.
• Personnel: Qualified and trained personnel involved in manufacturing and quality operations.
• Documentation: Comprehensive records of all manufacturing activities, quality control tests, and deviations.
• Quality Control: Established laboratory facilities and procedures for testing raw materials, in-process materials, and finished products.
• Process Validation: Documented evidence that a manufacturing process consistently produces a product meeting predetermined specifications.

API Supplier Requirements

API manufacturers must demonstrate control over their synthesis processes, impurity profiles, and physical characteristics (e.g., particle size distribution). This includes:

• Drug Master Files (DMFs): API suppliers often submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facility, and controls for the API. Innovator companies can then reference these DMFs in their drug applications.
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients).
• Impurity Profiling: Rigorous identification, quantification, and control of impurities, including genotoxic impurities, as per ICH Q3A/B guidelines.

Excipient Supplier Requirements

Excipient suppliers are increasingly subject to GMP expectations, especially for critical excipients. Regulatory bodies are moving towards a more harmonized approach to excipient quality. This often involves:

• Excipient Master Files (EMFs) or equivalent documentation: Providing detailed information on manufacturing processes, quality control, and supply chain security.
• Traceability: Ability to trace excipients from their origin through the manufacturing process.
• Compliance with Pharmacopeias: Meeting the specifications outlined in relevant pharmacopeias (e.g., USP-NF, Ph. Eur.).

Finished Dosage Form (FDF) Manufacturer Requirements

The FDF manufacturer is responsible for the final product's quality. This includes:

• Analytical Testing: Comprehensive testing of the finished product for identity, strength, quality, purity, and performance characteristics (e.g., dissolution).
• Stability Testing: Conducting stability studies to establish shelf-life and storage conditions.
• Packaging and Labeling: Ensuring that packaging materials protect the product and that labeling is accurate and compliant with regulatory requirements.
• Post-Market Surveillance: Monitoring product quality and safety after it has been released to the market.

Supply Chain Security and Traceability

Regulatory agencies are emphasizing robust supply chain security and traceability to prevent counterfeiting and ensure product integrity. This requires suppliers to have systems in place for:

• Serialization and Track-and-Trace: Implementing systems to uniquely identify and track drug products throughout the supply chain.
• Supplier Qualification and Auditing: A systematic process for qualifying and auditing all critical suppliers to ensure their compliance.

How Does the Supply Chain for Nexlizet Mitigate Risks?

The pharmaceutical supply chain for Nexlizet involves multiple points of potential disruption, including raw material shortages, manufacturing issues, and geopolitical instability. Risk mitigation strategies are critical for ensuring a continuous supply of the medication.

Dual Sourcing Strategies

To mitigate the risk of single-source dependency, the innovator likely employs dual sourcing for critical components.

• API Sourcing: Having at least two qualified suppliers for bempedoic acid and ezetimibe from different geographic regions can buffer against localized disruptions, such as natural disasters, regulatory actions against a specific facility, or trade disputes. This requires significant investment in qualifying secondary suppliers and maintaining sufficient inventory of materials from each.
• Excipient Sourcing: For high-volume excipients like microcrystalline cellulose or magnesium stearate, dual sourcing from different manufacturers ensures a stable supply. However, the cost and complexity of qualifying multiple suppliers need to be weighed against the risk.

Robust Quality Agreements and Audits

Strong contractual agreements and rigorous auditing processes are foundational to risk management.

• Quality Agreements: These legally binding documents detail the responsibilities of each party regarding quality, including specifications, testing methods, change control, and issue resolution. They define clear expectations for suppliers.
• Supplier Audits: Regular on-site audits by the innovator's quality assurance team assess a supplier's compliance with cGMP, their quality management systems, and their ability to meet contractual obligations. These audits can be scheduled or for-cause, depending on the criticality of the supplier and any identified risks.

Inventory Management and Buffer Stock

Maintaining adequate inventory levels is a direct defense against short-term supply disruptions.

• Raw Material Stockpiles: Holding buffer stock of key raw materials and APIs allows manufacturing to continue for a defined period if a primary supplier experiences an interruption.
• Finished Goods Inventory: Maintaining a reserve of finished Nexlizet tablets at various distribution points ensures product availability to patients. The optimal inventory level is a balance between the cost of holding stock and the risk of stock-outs.

Supply Chain Visibility and Monitoring

Enhanced visibility into the supply chain allows for proactive identification and management of potential risks.

• Information Sharing: Establishing channels for open communication with suppliers to be alerted to potential issues (e.g., production delays, raw material shortages) before they significantly impact the supply chain.
• Geopolitical and Economic Monitoring: Keeping abreast of global political developments, trade policies, and economic conditions that could affect the sourcing of raw materials or the logistics of transportation.
• Technological Solutions: Utilizing supply chain management software that provides real-time tracking of shipments, inventory levels, and supplier performance.

Business Continuity Planning (BCP)

Developing comprehensive BCPs for critical suppliers and manufacturing sites is essential.

• Contingency Plans: Identifying alternative manufacturing sites, transportation routes, and backup personnel for critical functions.
• Disaster Recovery: Ensuring that critical data and operational systems are backed up and can be rapidly restored in the event of a disaster.

What are the Key Considerations for Investors and R&D Teams Regarding Nexlizet's Supply Chain?

For investors and R&D teams, understanding the Nexlizet supply chain is critical for assessing commercial viability, potential risks, and future development opportunities.

Cost of Goods Sold (COGS)

The efficiency and stability of the supply chain directly impact the COGS for Nexlizet.

• API and Excipient Costs: The pricing and availability of bempedoic acid and ezetimibe APIs, as well as key excipients, are significant cost drivers. Negotiating favorable long-term contracts with suppliers, leveraging competitive bidding, and exploring cost-effective manufacturing routes are crucial.
• Manufacturing Efficiency: The choice of CMO, if applicable, and the efficiency of their operations influence manufacturing costs. Evaluating their yield rates, cycle times, and overhead contributes to COGS analysis.
• Logistics and Distribution: The cost of transporting raw materials and finished products, including warehousing and customs duties, adds to the overall COGS. Optimizing logistics networks and exploring regional manufacturing can yield savings.

Supply Reliability and Risk Mitigation

The ability to consistently supply Nexlizet to the market is paramount for revenue generation and market share.

• Supplier Diversification: Investors will assess the extent to which the company has diversified its supplier base to mitigate risks of single-source dependency. A concentration of critical suppliers in a single geographic region or with limited capacity presents a higher risk profile.
• Quality Compliance: The history of regulatory compliance for all supply chain partners is a key indicator of future reliability. Any past warnings, recalls, or significant quality issues with suppliers can signal potential future disruptions and increased regulatory scrutiny.
• Geopolitical and Environmental Risks: Proximity of key suppliers to areas prone to geopolitical instability, natural disasters, or stringent environmental regulations can introduce supply chain volatility.

Intellectual Property and Patent Landscape of Suppliers

While the primary focus is on the Nexlizet patent, understanding the IP landscape of key suppliers can reveal strategic advantages or potential challenges.

• Process Patents for APIs: Some suppliers may hold patents on specific manufacturing processes for bempedoic acid or ezetimibe that could influence cost or availability. Innovator companies typically aim to secure freedom to operate for their chosen manufacturing routes.
• Excipient Patents: While less common for standard excipients, novel excipient formulations or delivery systems could be patented, impacting the choice of materials.
• Future Supply Agreements: Understanding the IP landscape of potential future suppliers is important for long-term supply chain planning.

R&D Opportunities and Future Developments

The supply chain can also inform R&D strategies and future product lifecycle management.

• New API Manufacturing Routes: R&D teams may explore more efficient or cost-effective synthesis pathways for bempedoic acid or ezetimibe, potentially involving new suppliers or in-house capabilities.
• Formulation Improvements: Innovations in drug delivery or excipient technology could lead to improved formulations, requiring engagement with new specialized suppliers.
• Lifecycle Management: As patents approach expiration, understanding the cost structure and supply chain capabilities of potential generic manufacturers becomes crucial for competitive analysis.

Key Takeaways

• The Nexlizet supply chain relies on specialized API manufacturers for bempedoic acid and ezetimibe, alongside global excipient suppliers.
• Finished dosage form manufacturing is overseen by the innovator, Daiichi Sankyo/AstraZeneca, potentially involving contract manufacturing organizations.
• Strict adherence to cGMP, ICH guidelines, and robust quality agreements are mandated for all supply chain participants.
• Risk mitigation strategies include dual sourcing, comprehensive quality management, inventory control, and supply chain visibility.
• Investors and R&D teams must consider COGS, supply reliability, supplier compliance, and the IP landscape of supply chain partners for strategic decision-making.

FAQs

1. What is the primary regulatory body overseeing the Nexlizet supply chain?

The primary regulatory bodies are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which enforce cGMP and other pharmaceutical regulations globally.

2. Can a generic manufacturer easily substitute Nexlizet suppliers?

Substituting suppliers for a complex drug like Nexlizet is challenging. Generic manufacturers must demonstrate bioequivalence and obtain regulatory approval for their proposed API and excipient suppliers, which involves rigorous quality and process validation.

3. How does geographic concentration of suppliers affect Nexlizet's supply chain risk?

A high concentration of key suppliers in a single geographic region increases vulnerability to localized events such as natural disasters, political instability, or regional regulatory actions, thereby elevating supply chain risk.

4. What is the typical shelf life of Nexlizet, and how does it impact supply chain logistics?

The typical shelf life for Nexlizet is established through stability studies conducted by the innovator. A longer shelf life provides greater flexibility in inventory management and distribution, reducing the urgency of rapid turnover and minimizing the risk of product expiry.

5. Are there any known issues with the current Nexlizet supply chain reported by regulatory agencies?

As of the latest available public information, there are no widespread, officially reported supply chain disruptions or quality issues specifically concerning Nexlizet from major regulatory bodies. However, ongoing monitoring and supplier audits are standard practice.

Citations

[1] Grand View Research. (n.d.). Bempedoic Acid Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/bempedoic-acid-market